CA-125 which FDA has approved, is still the most effective and prevalent biomarker for ovarian cancer diagnosis in clinics; nevertheless, its low specificity makes it a less reliable approach and obligates the need for more precise biomarkers. Here, MUC16 is linked to ovarian carcinoma.